Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% IN PLASTIC CONTAINER vs HEMICLOR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Potassium is the major intracellular cation, essential for maintaining cellular membrane potential, nerve impulse transmission, and muscle contraction. Dextrose provides caloric supplementation.
Hemichlor (HEMICLOR) is a brand name for a combination product containing chlorpheniramine and pseudoephedrine. Chlorpheniramine is a first-generation antihistamine that antagonizes histamine at H1 receptor sites, reducing allergic symptoms. Pseudoephedrine is a sympathomimetic amine that directly stimulates alpha-adrenergic receptors, causing vasoconstriction and decongestion.
Correction of hypokalemia,Prevention of hypokalemia in patients at risk,Intravenous source of calories (dextrose)
Relief of symptoms associated with seasonal and perennial allergic rhinitis, including nasal congestion, sneezing, rhinorrhea, and pruritus,Off-label: Adjunctive treatment for acute sinusitis and common cold symptoms
Intravenous infusion at a rate not exceeding 10 m Eq/h (using 0.11% potassium chloride in 5% dextrose), typically 10-20 m Eq over 4-6 hours for mild hypokalemia, with a maximum concentration of 40 m Eq/L via peripheral line.
50-100 mg intravenously every 6 hours or 100 mg orally every 12 hours.
Potassium has no true elimination half-life as it is homeostatically regulated; the terminal half-life of a potassium load is approximately 8-12 hours in healthy individuals, but this is highly variable and dependent on renal function, aldosterone status, and body stores. In anuric patients, potassium clearance is minimal, and dangerous accumulation can occur within hours.
Terminal elimination half-life 18–24 hours in normal renal function; prolonged to 36–48 hours in moderate renal impairment (Cr Cl 30–50 m L/min); adjust dosing interval in renal disease.
Potassium is not metabolized; excreted primarily by kidneys. Dextrose undergoes glycolysis and oxidation to carbon dioxide and water.
Chlorpheniramine is extensively metabolized in the liver via CYP450 enzymes, primarily CYP2D6, and excreted renally as metabolites. Pseudoephedrine is partially metabolized in the liver by N-demethylation and excreted largely unchanged in urine; its metabolism is not significantly enzyme-dependent.
Primarily renal; >90% of potassium is excreted by the kidneys, with approximately 10% lost in feces. In steady state, urinary potassium excretion matches dietary intake (typically 40-120 m Eq/day). Dextrose is completely metabolized; unchanged dextrose excretion is negligible (<1% renal) in normoglycemic individuals.
Primarily renal (85–90% as unchanged drug via glomerular filtration and tubular secretion); biliary/fecal < 5%.
Potassium: negligible (<2%) protein binding; it is present as free ions. Dextrose: not protein bound.
70–80% (primarily to albumin).
Potassium: Vd ~0.5 L/kg (total body water); essentially distributes throughout the entire body water. Over 98% of total body potassium is intracellular; the Vd for administered potassium is larger than that for extracellular markers due to rapid cellular uptake. Dextrose distributes into total body water (Vd ~0.6 L/kg).
0.3–0.5 L/kg (indicates moderate tissue distribution).
Intravenous: 100% bioavailability. Not administered by other routes for potassium repletion due to poor tolerability and absorption (e.g., oral bioavailability of potassium chloride is 80-90%, but GI irritation limits use).
Oral: 40–60% (due to first-pass metabolism; food may reduce absorption).
GFR <30 m L/min: avoid use unless documented hypokalemia; maximum infusion rate 5 m Eq/h. GFR 30-50 m L/min: reduce rate to 5-10 m Eq/h. GFR >50 m L/min: standard dosing.
GFR 30-50 m L/min: 50 mg IV every 12h or 50 mg PO every 24h; GFR 10-29 m L/min: 50 mg IV every 24h or 25 mg PO every 24h; GFR <10 m L/min: 25 mg IV every 48h or avoid use.
No dose adjustment required for Child-Pugh class A or B. Class C: use with caution, monitor potassium levels and infusion rate; reduce maximum rate to 5 m Eq/h.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use.
0.5-1 m Eq/kg/dose IV, infused at a rate not exceeding 0.5-1 m Eq/kg/h; maximum concentration 40 m Eq/L for peripheral infusion. Adjust based on serum potassium levels.
5-10 mg/kg IV every 6h, max 100 mg/dose.
Reduce initial infusion rate to 5 m Eq/h; monitor renal function and serum potassium closely due to age-related decline in GFR; maximum concentration 40 m Eq/L.
Start at lower end of dosing range (50 mg IV every 12h or 50 mg PO every 24h) due to reduced renal function and increased sensitivity.
Potassium chloride injections are concentrated and must be diluted before administration. Rapid infusion may cause fatal hyperkalemia.
No FDA black box warning is present for HEMICLOR.
Risk of hyperkalemia, especially in renal impairment,Monitor serum potassium and ECG during administration,Do not administer undiluted,Use with caution in patients with cardiac disease, metabolic acidosis, or hypovolemia,Extravasation risk may cause tissue necrosis
Cardiovascular effects: Use with caution in patients with hypertension, ischemic heart disease, or arrhythmias,CNS depression: Chlorpheniramine may cause sedation; avoid concurrent use with alcohol or other CNS depressants,Monoamine oxidase inhibitor (MAOI) interaction: Concomitant use with MAOIs or within 14 days of discontinuation can precipitate hypertensive crisis,Urinary retention: Use cautiously in patients with prostatic hypertrophy or bladder neck obstruction,Photosensitivity: Chlorpheniramine may increase risk of photosensitivity reactions
Hyperkalemia,Severe renal impairment with oliguria or anuria,Untreated Addison's disease,Hyperchloremia,Conditions exacerbated by fluid overload
Hypersensitivity to chlorpheniramine, pseudoephedrine, or any component,Concurrent use of monoamine oxidase inhibitors (MAOIs) or within 14 days of MAOI therapy,Severe hypertension or severe coronary artery disease,Narrow-angle glaucoma,Urinary retention,Breastfeeding (relative contraindication due to pseudoephedrine excretion)
No specific food interactions. However, dietary potassium intake should be monitored when on high-dose potassium supplementation to avoid hyperkalemia. Avoid consuming large amounts of potassium-rich foods (e.g., bananas, oranges, tomatoes) without consulting a healthcare professional.
Avoid alcohol and grapefruit juice. Take with food to reduce gastrointestinal upset. Limit caffeine intake as it may worsen anxiety or gastrointestinal symptoms.
Potassium chloride and dextrose are not teratogenic at therapeutic doses. No increased risk of fetal malformations when used as electrolyte/carbohydrate replacement. However, maternal hyperkalemia or severe acidosis/fluid shifts may adversely affect fetal outcome. Trimester-specific risks not established.
Hemichlor (hydrochlorothiazide) is contraindicated in pregnancy due to risk of fetal/neonatal jaundice, thrombocytopenia, and electrolyte disturbances. First trimester: associated with neural tube defects in animal studies and possible oligohydramnios. Second/third trimester: risk of fetal bradycardia, hyponatremia, hypokalemia, and decreased placental perfusion.
Potassium and dextrose are normal constituents of breast milk. Intravenous administration results in minimal changes to milk composition. M/P ratio not applicable. Considered compatible with breastfeeding.
Hydrochlorothiazide is excreted in breast milk in low concentrations. M/P ratio approximately 0.04-0.06. No adverse effects reported in infants, but may suppress lactation at high doses. Use with caution, monitor infant for electrolyte disturbances.
No specific dose adjustments required. However, pregnant women may have increased plasma volume and altered renal function; standard dosing based on electrolyte and fluid deficits. Monitor serum potassium and glucose closely to avoid hyperkalemia or hyperglycemia.
Pregnancy increases volume of distribution and renal clearance of hydrochlorothiazide, potentially reducing peak serum concentration. However, due to fetal risks, thiazide diuretics are generally avoided in pregnancy. If essential, use lowest effective dose and monitor maternal/fetal status closely. No specific dose adjustment studies exist.
Potassium chloride in dextrose 5% is an intravenous solution for correction of hypokalemia and provision of maintenance fluids. Monitor serum potassium, renal function, and ECG during infusion. Maximum infusion rate: 10-20 m Eq/hour with continuous cardiac monitoring. Avoid in severe hyperkalemia, renal failure with oliguria, or conditions with potassium retention. Use central line if concentration >60 m Eq/L. Do not administer undiluted. Incompatible with amphotericin B, cefepime, and others.
HEMICLOR contains clidinium bromide (quaternary ammonium anticholinergic) and chlordiazepoxide (benzodiazepine). Monitor for anticholinergic side effects (dry mouth, blurred vision, urinary retention, constipation). Avoid use in patients with narrow-angle glaucoma, obstructive uropathy, or myasthenia gravis. Chlordiazepoxide may cause dependence; limit duration to 4-8 weeks. Use with caution in elderly due to increased sensitivity to anticholinergic effects and risk of falls.
This solution is given intravenously to replace potassium and provide hydration.,Report any pain, redness, or swelling at the IV site immediately.,Do not stop the infusion or adjust the rate on your own.,Tell your healthcare provider if you have kidney problems, heart disease, or are taking potassium supplements or certain blood pressure medications.,Inform your provider if you feel tingling, muscle weakness, irregular heartbeat, or confusion.
Take exactly as prescribed; do not increase dose or stop abruptly.,May cause drowsiness or dizziness; avoid driving or operating machinery until you know how it affects you.,Avoid alcohol and other CNS depressants.,Report any signs of urinary retention, severe constipation, or blurred vision.,Do not share with others; risk of dependence.,Store at room temperature away from moisture and heat.
"Atracurium besylate, a nondepolarizing neuromuscular blocking agent, may enhance the ulcerogenic potential of oral potassium chloride by reducing gastrointestinal motility and increasing local contact time of the potassium chloride tablet with the gastric and intestinal mucosa. This prolonged exposure can heighten the risk of gastrointestinal erosion, bleeding, or perforation, particularly in patients with pre-existing lesions or receiving high-dose potassium supplementation. Clinically, this interaction necessitates close monitoring for signs of gastrointestinal injury when these agents are coadministered."
"Methscopolamine bromide, an anticholinergic agent, reduces gastrointestinal motility and delays gastric emptying, which can prolong the contact time of orally administered Potassium chloride (KCl) tablets or capsules with the gastric mucosa. This increased exposure to high concentrations of potassium in the gastrointestinal tract potentiates the local ulcerogenic effect of KCl, leading to a higher risk of esophageal, gastric, or intestinal erosions, ulcers, hemorrhage, perforation, or stricture formation. Clinically, this interaction may present with dysphagia, epigastric pain, hematemesis, melena, or signs of acute abdomen."
"Fesoterodine, an anticholinergic agent used for overactive bladder, can reduce gastric motility and prolong gastrointestinal transit time. This effect may increase the local contact time of potassium chloride tablets with the gastrointestinal mucosa, potentiating the ulcerogenic risk of potassium chloride, which can cause esophageal or intestinal ulceration, stenosis, or perforation. The interaction is clinically significant in patients with pre-existing gastrointestinal motility disorders or those taking high-dose potassium supplements."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% IN PLASTIC CONTAINER vs HEMICLOR, answered by our medical review team.
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% IN PLASTIC CONTAINER is a Electrolyte Supplement that works by Potassium is the major intracellular cation, essential for maintaining cellular membrane potential, nerve impulse transmission, and muscle contraction. Dextrose provides caloric supplementation.. HEMICLOR is a Electrolyte Supplement that works by Hemichlor (HEMICLOR) is a brand name for a combination product containing chlorpheniramine and pseudoephedrine. Chlorpheniramine is a first-generation antihistamine that antagonizes histamine at H1 receptor sites, reducing allergic symptoms. Pseudoephedrine is a sympathomimetic amine that directly stimulates alpha-adrenergic receptors, causing vasoconstriction and decongestion.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% IN PLASTIC CONTAINER and HEMICLOR depend on the specific clinical indication. These are both Electrolyte Supplement agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous infusion at a rate not exceeding 10 m Eq/h (using 0.11% potassium chloride in 5% dextrose), typically 10-20 m Eq over 4-6 hours for mild hypokalemia, with a maximum concentration of 40 m Eq/L via peripheral line.. The standard adult dose of HEMICLOR is: 50-100 mg intravenously every 6 hours or 100 mg orally every 12 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% IN PLASTIC CONTAINER and HEMICLOR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. Potassium chloride and dextrose are not teratogenic at therapeutic doses. No increased risk of fetal malformations when used as electrolyte/carbohydrate replacement. However, mater. HEMICLOR is classified as Category C. Hemichlor (hydrochlorothiazide) is contraindicated in pregnancy due to risk of fetal/neonatal jaundice, thrombocytopenia, and electrolyte disturbances. First trimester: associated . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.